Annual D&A
$9.84 M
+$3.77 M+61.98%
31 December 2023
Summary:
Adaptimmune Therapeutics annual depreciation & amortization is currently $9.84 million, with the most recent change of +$3.77 million (+61.98%) on 31 December 2023. During the last 3 years, it has risen by +$2.25 million (+29.58%). ADAP annual D&A is now at all-time high.ADAP Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$2.82 M
+$76.00 K+2.77%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly depreciation & amortization is currently $2.82 million, with the most recent change of +$76.00 thousand (+2.77%) on 30 September 2024. Over the past year, it has dropped by -$74.00 thousand (-2.56%). ADAP quarterly D&A is now -2.56% below its all-time high of $2.89 million, reached on 30 September 2023.ADAP Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$11.26 M
-$74.00 K-0.65%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM depreciation & amortization is currently $11.26 million, with the most recent change of -$74.00 thousand (-0.65%) on 30 September 2024. Over the past year, it has increased by +$2.85 million (+33.96%). ADAP TTM D&A is now -0.65% below its all-time high of $11.34 million, reached on 30 June 2024.ADAP TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +62.0% | -2.6% | +34.0% |
| 3 y3 years | +29.6% | +93.8% | +66.2% |
| 5 y5 years | +26.0% | +45.1% | +40.5% |
ADAP Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +62.0% | -2.6% | +96.1% | -0.7% | +85.4% |
| 5 y | 5 years | at high | +62.0% | -2.6% | +96.2% | -0.7% | +85.4% |
| alltime | all time | at high | >+9999.0% | -2.6% | +2891.5% | -0.7% | >+9999.0% |
Adaptimmune Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.82 M(+2.8%) | $11.26 M(-0.7%) |
| June 2024 | - | $2.74 M(-3.1%) | $11.34 M(+4.7%) |
| Mar 2024 | - | $2.83 M(-1.4%) | $10.82 M(+10.0%) |
| Dec 2023 | $9.84 M(+62.0%) | $2.87 M(-0.7%) | $9.84 M(+17.1%) |
| Sept 2023 | - | $2.89 M(+29.6%) | $8.41 M(+20.0%) |
| June 2023 | - | $2.23 M(+21.0%) | $7.00 M(+10.8%) |
| Mar 2023 | - | $1.84 M(+28.4%) | $6.33 M(+4.1%) |
| Dec 2022 | $6.08 M(-7.5%) | $1.44 M(-3.6%) | $6.08 M(-11.6%) |
| Sept 2022 | - | $1.49 M(-3.9%) | $6.87 M(+0.5%) |
| June 2022 | - | $1.55 M(-2.7%) | $6.83 M(+1.6%) |
| Mar 2022 | - | $1.59 M(-28.6%) | $6.73 M(+2.4%) |
| Dec 2021 | $6.57 M(-13.5%) | $2.23 M(+53.6%) | $6.57 M(-3.1%) |
| Sept 2021 | - | $1.45 M(+0.8%) | $6.78 M(-1.7%) |
| June 2021 | - | $1.44 M(+0.5%) | $6.89 M(-5.9%) |
| Mar 2021 | - | $1.44 M(-41.2%) | $7.32 M(-3.6%) |
| Dec 2020 | $7.59 M(-5.2%) | $2.44 M(+55.8%) | $7.59 M(+4.8%) |
| Sept 2020 | - | $1.57 M(-16.2%) | $7.24 M(-4.9%) |
| June 2020 | - | $1.87 M(+9.4%) | $7.62 M(-1.4%) |
| Mar 2020 | - | $1.71 M(-18.3%) | $7.73 M(-3.5%) |
| Dec 2019 | $8.01 M | $2.09 M(+7.8%) | $8.01 M(-0.1%) |
| Sept 2019 | - | $1.94 M(-1.9%) | $8.02 M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $1.98 M(-0.8%) | $7.98 M(+0.8%) |
| Mar 2019 | - | $2.00 M(-4.9%) | $7.92 M(+1.4%) |
| Dec 2018 | $7.81 M(+44.0%) | $2.10 M(+9.9%) | $7.81 M(+4.8%) |
| Sept 2018 | - | $1.91 M(-0.6%) | $7.45 M(+5.8%) |
| June 2018 | - | $1.92 M(+2.0%) | $7.04 M(+12.5%) |
| Mar 2018 | - | $1.88 M(+8.3%) | $6.26 M(+15.4%) |
| Dec 2017 | $5.42 M(+65.0%) | $1.74 M(+15.6%) | $5.42 M(+19.0%) |
| Sept 2017 | - | $1.50 M(+32.3%) | $4.56 M(+17.7%) |
| June 2017 | - | $1.14 M(+8.6%) | $3.87 M(+8.0%) |
| Mar 2017 | - | $1.05 M(+19.7%) | $3.59 M(+9.2%) |
| Dec 2016 | $3.29 M(+163.9%) | $874.00 K(+6.8%) | $3.29 M(+36.2%) |
| Sept 2016 | - | $818.00 K(-3.7%) | $2.41 M(+16.5%) |
| June 2016 | - | $849.00 K(+14.0%) | $2.07 M(+69.5%) |
| Mar 2016 | - | $745.00 K(+56.6%) | $1.22 M(+96.0%) |
| Dec 2015 | $1.25 M(+69.4%) | - | - |
| Sept 2015 | - | $475.80 K(+223.5%) | $622.90 K(+158.1%) |
| June 2015 | $735.00 K(+206.3%) | - | - |
| Dec 2014 | - | $147.10 K(+56.2%) | $241.30 K(+156.2%) |
| Sept 2014 | - | $94.20 K | $94.20 K |
| June 2014 | $240.00 K(+426.3%) | - | - |
| June 2013 | $45.60 K | - | - |
FAQ
- What is Adaptimmune Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual D&A year-on-year change?
- What is Adaptimmune Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly D&A year-on-year change?
- What is Adaptimmune Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM D&A year-on-year change?
What is Adaptimmune Therapeutics annual depreciation & amortization?
The current annual D&A of ADAP is $9.84 M
What is the all time high annual D&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual depreciation & amortization is $9.84 M
What is Adaptimmune Therapeutics annual D&A year-on-year change?
Over the past year, ADAP annual depreciation & amortization has changed by +$3.77 M (+61.98%)
What is Adaptimmune Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of ADAP is $2.82 M
What is the all time high quarterly D&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly depreciation & amortization is $2.89 M
What is Adaptimmune Therapeutics quarterly D&A year-on-year change?
Over the past year, ADAP quarterly depreciation & amortization has changed by -$74.00 K (-2.56%)
What is Adaptimmune Therapeutics TTM depreciation & amortization?
The current TTM D&A of ADAP is $11.26 M
What is the all time high TTM D&A for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM depreciation & amortization is $11.34 M
What is Adaptimmune Therapeutics TTM D&A year-on-year change?
Over the past year, ADAP TTM depreciation & amortization has changed by +$2.85 M (+33.96%)